Although the link between bacterial infections and tumor necrosis factor (TNF) inhibitors is becoming increasingly established, much less is known about the risk of viral infections with these agents. The authors of this Review highlight emerging reports of viral infections in patients receiving anti-TNF therapy, and discuss treatment implications and potential strategies for preventing such infections.
- Seo Young Kim
- Daniel H. Solomon
